

Stm 天主教聖馬爾定醫院

(一) 小細胞肺癌化療處方集

最初出版日期：99.01

最後更新日期：108.03

癌別：小細胞肺癌	
CCRT	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥4hrs) + Etoposide 200-300 mg/m² (N/S 500 c.c.; ≥3rs,divided or single dose) q 4 wks (Cancer Treat. Rep.1979; 63:1593-7)</p> <p>(2) Cisplatin 60 mg/m² + Etoposide 200-300 mg/m² +Endoxan 600 mg/m² (N/S 300 c.c.; 2hrs) q 4 wks (JCO 1987 ; 5:1874-9) (R.R. :88%(C.R.:57%))</p>
Palliative	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥4hrs) + Etoposide 200-300 mg/m² (N/S 500 c.c.; ≥3rs,divided or single dose) q 4 wks (Cancer Treat. Rep.1979; 63:1593-7)</p> <p>(2) Cisplatin 60 mg/m² + Etoposide 200-300 mg/m² +Endoxan 600 mg/m² (N/S 300 c.c.; 2hrs) q 4 wks (JCO 1987 ; 5:1874-9) (R.R. :88%(C.R.:57%))</p> <p>(3) Irinotecan 140,150,160 mg/m² (N/S 500 c.c.; 3 hrs) + Etoposide 150 mg/m² (N/S 500 c.c.; ≥3hrs) q 2wks (for Cisplatin – resistant) (Oncology 2002 Apr.,16(4):419-25)</p> <p>(4) Topotecan 1, 1.2 mg/m² /d (N/S 100 c.c.,30 mins)* 3-5 days q 4 wks (for cisplatin – resistant, 2nd-line) (Drugs 1999 Sep;58(3):533-51)</p> <p>(5) Carboplatin (AUC 6) (N/S 500 cc; 6 hrs) + Etoposide 100 mg/m² (N/S 500 cc; 3hrs on D1-D3) (for CCr < 60)</p> <p>(6) Consider Bevacizumab 5mg/kg/cycle (JCO, Nov. 2011 33:4436-4441)</p>

(二) 非小細胞肺癌化療處方集

最初出版日期：99.01

最後更新日期：108.06

癌別：非小細胞肺癌	
CCRT	(1) Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 wks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.;10 mins) or (P.O.) 55-70 mg/m ² q 2 wks (JCO 1994; 12: 360-7) (2) Cisplatin 60 mg/m ² + Etoposide 200-300 mg/m ² (N/S 500 c.c.; ≥3rs,divided or single dose) q 4 wks (Cancer Treat. Rep.1979; 63:1593-7)
Neoadjuvant(術前)	(1) Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 wks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.;10 mins) or (P.O.) 55-70 mg/m ² q 2 wks (JCO 1994; 12: 360-7) (2) Cisplatin 60 mg/m ² q 4 wks + Gemcitabine 1000 mg/m ² (N/S 100 c.c.; 30 mins) q 2 wks (Annals of Oncology Vol.10 Feb 1999, pp 217-221) (JCO 1997; 15:744-9) (3) Cisplatin 60 mg/m ² q 4 wks + Docetaxel 35,40 mg/m ² (N/S 100 c.c.; 1 hr) q 2wks (Oncology Jul. 01, 1997) (4) Cisplatin 60 mg/m ² q 4 wks + Paclitaxel 85 mg/m ² (N/S 300 c.c.; 2 hrs) q 2 wks (JCO 1995; 13:1860-70) (5) Cisplatin 60 mg/m ² + Pemetrexed 500 mg/m ² (N/S 100 c.c.; 20 mins) q 4wks (for NSCLC 且 non-squamous cancer) (Annals of Oncology Vol.22 Nov. 2011, pp 2466-2470)
Adjuvant(術後)	Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 weks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.;10 mins) or (P.O.) 55-70 mg/m ² q 2 wks * 4 cycles
Palliative(無法手術)	(1) Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 wks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.;10 mins) or (P.O.) 55-70 mg/m ² q 2 wks (JCO 1994; 12: 360-7) (2) Cisplatin 60 mg/m ² q 4 wks + Gemcitabine 1000 mg/m ² (N/S 100 c.c.; 30 mins) q 2 wks (Annals of Oncology Vol.10 Feb 1999, pp 217-221) (JCO 1997; 15:744-9) (3) Cisplatin 60 mg/m ² q 4 wks + Docetaxel 35,40 mg/m ² (N/S 100 c.c.; 1 hr) q 2wks (Oncology Jul. 01, 1997) (4) Cisplatin 60 mg/m ² q 4 wks + Paclitaxel 85 mg/m ² (N/S 300 c.c.; 2 hrs) q 2 wks (JCO 1995; 13:1860-70) (5) Cisplatin 60 mg/m ² + Pemetrexed 500 mg/m ² (N/S 100 c.c.; 20 mins) q 4wks (for NSCLC 且 non-squamous cancer) (Annals of Oncology Vol.22 Nov. 2011, pp 2466-2470)

癌別: 非小細胞肺癌

以上之化療處方用藥,若於 palliative use 可不合併 cisplatin

Besides, consider the following agents:

- * Bevacizumab 5mg/kg/cycle (The Oncologist Aug 14, 2007)
- * Gefitinib 250mg gd (健保條例)
- * Erlotinib 150mg or 100mg gd (健保條例)
- * Afatinib 40mg or 30mg gd (健保條例)
- * Crizotinib 250 mg bid (健保條例)
- * Ceritinib 750 mg qd (健保條例)
- * Alectinib 600mg (with meals) bid (Cancer Cell Vol. 19 May 2011 pp 679-690)
- * Ramucirumab 6,8mg/kg/dose (N/S 300c.c; 90mins) (approved by FDA on 4, 21, 2014) (Am Health Drug Benefits 2015, Mar; 8:49-53)